Studies of platelet activating factor (PAF) antagonists from microbial products. III. Pharmacological studies of FR-900452 in animal models.

Publisher Website
Google Scholar
Abstract
1-Methyl-3-[1-[5-methylthiomethyl-6-oxo-3-(2-oxo-3-cyclopenten-1-ylidene)-2-piperazinyl]-ethyl]-2-indolinone (FR-900452), isolated from the fermentation broth of Streptomyces phaeofaciens No. 7739, is a specific inhibitor of rabbit platelet aggregation induced by platelet activating factor (PAF) in vitro. In order to ascertain the FAF antagonistic activity of FR-900452 in vivo, the effects of this compound on PAF-induced bronchoconstriction in guinea-pigs, hypotension in rats and vascular permeability increase in mice were examined. The compound significantly inhibited the bronchoconstriction, the hypotension and the vascular permeability increase at a dosage of less than 10 mg/kg, i.v., and the hypotensive actions induced by i.v. administration of histamine (His, 100 .mu.g/kg), acetylcholine (Ach, 1 .mu.g/kg), bradykinin (Bk, 10 .mu.g/kg) and isoproterenol (Isp, 1 .mu.g/kg) were not altered by FR-900452 (10 mg/kg, i.v.). Therefore, to determine whether endogeneous PAF contributes to the pathogenesis if immunoglobulin E (IgE)-mediated anaphylaxis, the effect of FR-900452 on the hypotension induced by IgE-mediated anaphylaxis in rats was tested. The compound significantly prevented the hypotension at a dose of 10 mg/kg, i.v. The results suggest that PAF may play a role in the pathogenesis of the IgE-mediated hypotension in rats.

This publication has 11 references indexed in Scilit: